Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing neovasculature after local irradiation

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Liu, Tao ^a   Xie, Congying ^b   Ma, Hong ^a   Zhang, Sheng ^a   Liang, Yicheng ^a   Shi, Liangliang ^a   Yu, Dandan ^a   Feng, Yiming ^a   Zhang, Tao ^a   Wu, Gang ^a  

^a UNION HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; GR-1 PROTEIN, MOUSE; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL; BONE MARROW CELL; CARCINOMA, LEWIS LUNG; CELL MOTION; DISEASE COURSE; DISEASE MODEL; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; MALE; METABOLISM; MONONUCLEAR CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION RESPONSE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, CD11B; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MICE; MYELOID CELLS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899621981     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04833     Document Type: Article

References (48)

1. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
2. Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182, 4499-4506 (2009).
3. Tennyson, A. G. & Lippard, S. J. Generation, translocation, and action of nitric oxide in living systems. Chem Biol 18, 1211-1220 (2011).
4. Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186 (1971).
5. Kerbel, R. S. Tumor angiogenesis. N Engl J Med 358, 2039-2049 (2008). (Pubitemid 351656458)
6. Allavena, P., Sica, A., Solinas, G., Porta, C. & Mantovani, A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66, 1-9 (2008). (Pubitemid 351324128)
7. Coffelt, S. B., Hughes, R. & Lewis, C. E. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796, 11-18 (2009).
8. Solinas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAMs) as major players of the cancer-related inflammation. J Leukoc Biol 86, 1065-1073 (2009).
9. Venneri, M. A. et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109, 5276-5285 (2007). (Pubitemid 46890548)
10. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and amesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005). (Pubitemid 41317592)
11. Vajkoczy, P. et al. Multistep nature of microvascular recruitment of ex vivoexpanded embryonic endothelial progenitor cells during tumor angiogenesis. J Exp Med 197, 1755-1765 (2003). (Pubitemid 36745350)
12. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005). (Pubitemid 40692295)
13. Duda, D. G. et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107, 2774-2776 (2006).
14. Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8, 618-631 (2008).
15. Marx, J. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science 319, 154-156 (2008).
16. Yan, H. H. et al. Gr-11CD11b1 myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 70, 6139-6149 (2010).
17. Sinha, P. & Clements, V. K. Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174, 636-645 (2005). (Pubitemid 40094255)
18. Duda, D. G. et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17, 2074-2080 (2011).
19. Petit, I., Jin, D. & Rafii, S. The SDF-1-CXCR4 signaling pathway: amolecular hub modulating neo-angiogenesis. Trends Immunol 28, 299-307 (2007). (Pubitemid 46963141)
20. Yang, L. et al. Expansion of myeloid immune suppressor Gr1CD11b1 cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004). (Pubitemid 39361441)
21. Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. & Albelda, S. M. Gemcitabine selectively eliminates splenic GR-11/CD11b1 myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11, 6713-6721 (2005). (Pubitemid 41339014)
22. Ahn, G. O. & Brown, J. M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193-205 (2008). (Pubitemid 351318369)
23. Xu, J. et al. CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer. Cancer Res 73, 2782-2794 (2013).
24. Kozin, S. V. et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 70, 5679-5685 (2010).
25. Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120, 694-705 (2010).
26. Welford, A. F. et al. TIE2-expressingmacrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 121, 1969-1973 (2011).
27. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102, 1555-1577 (2010).
28. Seung, L. P., Weichselbaum, R. R., Toledano, A., Schreiber, K. & Schreiber, H. Radiation can inhibit tumor growth indirectly while depleting circulating leukocytes. Radiat Res 146, 612-618 (1996). (Pubitemid 26412376)
29. Li, H. et al. Different neurotropic pathogens elicit neurotoxic CCR9-or neurosupportive CXCR3-expressing microglia. The Journal of Immunology 177, 3644-3656 (2006). (Pubitemid 44359896)
30. Fleming, T., Fleming, M. & Malek, T. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5mAbto granulocyte- differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 151, 2399-2408 (1993). (Pubitemid 23264492)
31. Weidner, N. Current pathologic methods for measuring intratumoralmicrovessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36, 169-180 (1995).
32. Weidner, N. et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84, 1875-1887 (1992). (Pubitemid 23004615)
33. Tseng, D., Vasquez-Medrano, D. & Brown, J. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br J Cancer 104, 1805-1809 (2011).
34. Hatse, S., Princen, K., Bridger, G., De Clercq, E. & Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527, 255-262 (2002). (Pubitemid 35253875)
35. Singh, S. & Gupta, A. K. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 67, 1211-1224 (2011).
36. Cianchi, F. et al. Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: correlation with tumor angiogenesis. Dig Liver Dis 42, 20-27 (2010).
37. Rofstad, E. K., Mathiesen, B., Henriksen, K., Kindem, K. & Galappathi, K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced upregulation of metastasis-promoting gene products. Cancer Res 65, 2387-2396 (2005). (Pubitemid 40490150)
38. Zips, D. et al. Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse. Int J Radiat Biol 77, 1185-1193 (2001). (Pubitemid 33111855)
39. Kong, D., Li, Y., Wang, Z., Banerjee, S. & Sarkar, F. H. Inhibition of angiogenesis and invasion by 3, 39-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67, 3310-3319 (2007). (Pubitemid 46724870)
40. Pozzi, A., LeVine, W. F. & Gardner, H. A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21, 272-281 (2002). (Pubitemid 34102135)
41. Kostourou, V. et al. The role of tumour-derived iNOS in tumour progression and angiogenesis. Br J Cancer 104, 83-90 (2011).
42. Cullis, E. R. et al. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc Res 71, 76-84 (2006).
43. Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nat Rev Cancer 6, 521-534 (2006). (Pubitemid 43980541)
44. Jadeski, L. C. & Lala, P. K. Nitric oxide synthase inhibition by N(G)-nitro-Larginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 155, 1381-1390 (1999). (Pubitemid 29488945)
45. Thomsen, L. L. et al. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400 W, a novel inhibitor. Cancer Res 57, 3300-3304 (1997). (Pubitemid 27351750)
46. Sikora, A. G. et al. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16, 1834-1844 (2010).
47. Ng, Q. S. et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8, 111-118 (2007).
48. Konopka, T. E. et al. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 61, 3182-3187 (2001). (Pubitemid 32691973)